Cargando…

Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer

OBJECTIVE: Although targeted approaches have become available in second‐ and third‐line settings, platinum‐based chemotherapy remains the standard first‐line treatment for advanced muscle‐invasive bladder cancer (MIBC). Therefore, the prediction of platinum resistance is of utmost clinical importanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olah, Csilla, Reis, Henning, Hoffmann, Michèle J., Mairinger, Fabian, Ting, Saskia, Hadaschik, Boris, Krafft, Ulrich, Grünwald, Viktor, Nyirady, Peter, Varadi, Melinda, Győrffy, Balázs, Kiss, Andras, Szekely, Eszter, Sjödahl, Gottfrid, Szarvas, Tibor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028049/ https://www.ncbi.nlm.nih.gov/pubmed/36204983 http://dx.doi.org/10.1002/cam4.5324

Ejemplares similares

High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy
por: Krafft, Ulrich, et al.
Publicado: (2021)

Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study
por: Váradi, Melinda, et al.
Publicado: (2023)

Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial Carcinoma
por: Kovács, Petra Terézia, et al.
Publicado: (2022)

MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients
por: Szarvas, Tibor, et al.
Publicado: (2020)

High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma
por: Széles, Ádám, et al.
Publicado: (2022)

Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis
por: Széles, Ádám, et al.
Publicado: (2022)

Why are upper tract urothelial carcinoma two different diseases?
por: Szarvas, Tibor, et al.
Publicado: (2016)

Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
por: Olah, Csilla, et al.
Publicado: (2020)

Comprehensive Analysis of the Prognostic Value of Circulating MMP-7 Levels in Urothelial Carcinoma: A Combined Cohort Analysis, Systematic Review, and Meta-Analysis
por: Kubik, András, et al.
Publicado: (2023)

Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas
por: Varadi, Melinda, et al.
Publicado: (2023)

Correction to: COVID-19 research: promising tracks leading to uro-oncology
por: Fazekas, Tamás, et al.
Publicado: (2020)

COVID-19 research: promising tracks leading to uro-oncology
por: Tamás, Fazekas, et al.
Publicado: (2020)

Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients—a systematic review and meta-analysis
por: Fazekas, Tamás, et al.
Publicado: (2022)

Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data
por: Reis, Henning, et al.
Publicado: (2018)

Molecular classification of urothelial carcinoma: global mRNA classification versus tumour‐cell phenotype classification
por: Sjödahl, Gottfrid, et al.
Publicado: (2017)

Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?
por: Szarvas, Tibor, et al.
Publicado: (2019)

Molecular pathology of the luminal class of urothelial tumors
por: Bernardo, Carina, et al.
Publicado: (2019)

HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
por: Eriksson, Pontus, et al.
Publicado: (2017)

Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems
por: Eriksson, Pontus, et al.
Publicado: (2015)

Molecular subtype classification of urothelial carcinoma in Lynch syndrome
por: Therkildsen, Christina, et al.
Publicado: (2018)

Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder Cancer
por: Wessolly, Michael, et al.
Publicado: (2022)

Integrative epigenomic analysis of differential DNA methylation in urothelial carcinoma
por: Aine, Mattias, et al.
Publicado: (2015)

A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort
por: Marzouka, Nour-al-dain, et al.
Publicado: (2018)

High-soluble CGA levels are associated with poor survival in bladder cancer
por: Szarvas, T, et al.
Publicado: (2019)

The Urothelial Transcriptomic Response to Interferon Gamma: Implications for Bladder Cancer Prognosis and Immunotherapy
por: Baker, Simon C., et al.
Publicado: (2022)

Recurring urothelial carcinomas show genomic rearrangements incompatible with a direct relationship
por: Marzouka, Nour-Al-Dain, et al.
Publicado: (2020)

Detailed Analysis of Focal Chromosome Arm 1q and 6p Amplifications in Urothelial Carcinoma Reveals Complex Genomic Events on 1q, and SOX4 as a Possible Auxiliary Target on 6p
por: Eriksson, Pontus, et al.
Publicado: (2013)

A Systematic Study of Gene Mutations in Urothelial Carcinoma; Inactivating Mutations in TSC2 and PIK3R1
por: Sjödahl, Gottfrid, et al.
Publicado: (2011)

Do budget constraints limit access to health care? Evidence from PCI treatments in Hungary
por: Kiss, András, et al.
Publicado: (2023)

Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma
por: Sjödahl, Gottfrid, et al.
Publicado: (2019)

Lifestyle-, environmental-, and additional health factors associated with an increased sperm DNA fragmentation: a systematic review and meta-analysis
por: Szabó, Anett, et al.
Publicado: (2023)

Prevalence of APC and PTEN Alterations in Urachal Cancer
por: Nagy, Nikolett, et al.
Publicado: (2020)

Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma
por: Lindgren, David, et al.
Publicado: (2012)

Serum and tissue syndecan-1 levels in renal cell carcinoma
por: Niedworok, Christian, et al.
Publicado: (2020)

Correction to: A new technological approach in diagnostic pathology: mass spectrometry imaging-based metabolomics for biomarker detection in urachal cancer
por: Neumann, Judith Martha, et al.
Publicado: (2021)

A new technological approach in diagnostic pathology: mass spectrometry imaging-based metabolomics for biomarker detection in urachal cancer
por: Neumann, Judith Martha, et al.
Publicado: (2021)

Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer
por: Kocsmár, Ildikó, et al.
Publicado: (2022)

Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients
por: Rehme, Christian, et al.
Publicado: (2021)

DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status
por: Lauss, Martin, et al.
Publicado: (2012)

Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma
por: Droop, Johanna, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v2ruq0iu7fev4m701cklfkttja